Whitehawk Therapeutics Inc

Whitehawk Therapeutics Inc reported a net loss of $20.6 million for FY 2025, a significant improvement from a $63.7 million net loss in FY 2024, primarily driven by an $87.3 million gain on the sale of its FYARRO business. Total revenue was $7.1 million, a sharp decline from $26.0 million in the prior year, reflecting the divestiture of the FYARRO commercial product in March 2025. The company incurred substantial operating expenses of $121.5 million, dominated by $91.0 million in research and development costs for its new ADC pipeline. Cash and short-term investments totaled $145.7 million at year-end, providing runway for clinical development of its three investigational ADC therapies targeting PTK7, MUC16, and SEZ6.

Key Takeaways